Keenova Therapeutics plc: restructuring charge — Mallinckrodt to discontinue StrataGraft due to slow uptake; expects ~$15M in exit costs and impairment charge.

Keenova Therapeutics plc

On Jan 4, 2024, committed to cease commercialization and wind down StrataGraft by end of Q1 2025.
Pre-tax charges ~$15M excluding impairments: $5M termination benefits, $5M contract/lease termination, $5M other costs; mostly cash charges in Q1 2024.
Impairment charge on StrataGraft inventory expected in Q1 2024 but amount not yet estimable due to fresh-start accounting from Nov 2023 bankruptcy emergence.
Decision driven by slower-than-anticipated commercial uptake and clinical trial enrollment; evaluating sale or out-license.
Majority of charges in Q1 2024, remainder through FY2024 and Q1 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Keenova Therapeutics plc announced a restructuring with charges of approximately $15 million affecting StrataGraft product (approximately $5 million of one-time termination benefits).

Type: restructuring
Charge: approximately $15 million
Affected area: StrataGraft product
Headcount: approximately $5 million of one-time termination benefits

Exact text from the filing

the Company currently expects to incur pre-tax charges, exclusive of impairments, of approximately $15 million, which include (i) approximately $5 million of one-time termination benefits, (ii) approximately $5 million in contract and lease termination costs, and (iii) approximately $5 million of other associated costs.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.7

Keenova Therapeutics plc announced a impairment affecting StrataGraft inventory.

Type: impairment
Affected area: StrataGraft inventory

Exact text from the filing

the Company expects to recognize an impairment charge related to its existing StrataGraft inventory in the first fiscal quarter of 2024. The Company cannot currently estimate the size or materiality of the impairment charge because it is currently assessing the fair value of its assets as a result of the adoption of fresh-start accounting

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001104659-24-002537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.